Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
Petros D GrivasDamien PouesselChandler H ParkPhilippe BarthelemyManojkumar BupathiDaniel P PetrylakArchana M AgarwalSumati V GuptaAude FléchonChethan RamamurthyNancy B DavisAlejandro Recio-BoilesCora N SternbergAstha BhatiaCabilia PichardoMitch SiereckiJulia TonelliHuafeng ZhouScott T TagawaYohann LoriotPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
SG plus pembrolizumab demonstrated a high response rate with an overall manageable toxicity profile in patients with mUC who progressed after platinum-based chemotherapy. No new safety signals were detected. These data support further evaluation of SG plus CPI in mUC.